Pathstone Family Office’s iShares Biotechnology ETF IBB Stock Holding History

Pathstone Family Office’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$1.82M	Buy	14,845 +9,557	+181%	+$1.22M	0.01%	488
2023 Q2	$671K	Buy	+5,288	New	+$687K	0.01%	624
2022 Q4	–	Sell	-6,742	Closed	-$789K	–	1539
2022 Q3	$789K	Buy	+6,742	New	+$837K	0.01%	863
2021 Q1	–	Sell	-312	Closed	-$47K	–	969
2020 Q4	$47K	Buy	+312	New	+$44.6K	﹤0.01%	525
2020 Q3	–	Sell	-290	Closed	-$40K	–	892
2020 Q2	$40K	Hold	290	–	–	﹤0.01%	342
2020 Q1	$31K	Hold	290	–	–	﹤0.01%	366
2019 Q4	$349K	Buy	+290	New	+$32.4K	﹤0.01%	340
2015 Q4	–	Sell	-45	Closed	-$5K	–	128
2015 Q3	$5K	Buy	+45	New	+$5.4K	0.01%	124
2013 Q4	–	Sell	-225	Closed	-$16K	–	265
2013 Q3	$16K	Buy	+225	New	+$14.7K	0.07%	144

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Pathstone Family Office's IBB Position: Q3 2023 in Review

Pathstone Family Office increased its iShares Biotechnology ETF (IBB) stake by 181% in Q3 2023, buying an estimated $1.22M and bringing the position to 14,845 shares worth $1.82M. The position accounts for 0.01% of the portfolio, ranked #488.

Pathstone Family Office first reported a position in IBB in Q3 2013 and has held it in 9 quarters since. 832 funds tracked by Wall St. Rank hold IBB as of Q3 2023.

Pathstone Family Office held 14,845 shares of iShares Biotechnology ETF worth $1.82M as of Q3 2023.
Pathstone Family Office bought 9,557 iShares Biotechnology ETF shares in Q3 2023, an estimated $1.22M.
iShares Biotechnology ETF made up 0.01% of Pathstone Family Office's portfolio in Q3 2023, its #488 holding.
Pathstone Family Office first reported a position in iShares Biotechnology ETF in Q3 2013 and has held it in 9 quarters since.
832 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.